Apomorphine
- Generic Name
- Apomorphine
- Brand Names
- Apokyn
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17NO2
- CAS Number
- 58-00-4
- Unique Ingredient Identifier
- N21FAR7B4S
- Background
Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
Apomorphine was granted FDA approval on 20 April 2004.
- Indication
Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.
- Associated Conditions
- Mobility decreased
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03292016
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Parkinson's Disese Treatment Center of SW Florida, Port Charlotte, Florida, United States
🇺🇸QUEST Research Institute, Farmington Hills, Michigan, United States
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- Conditions
- Parkinson's DiseaseOff Episodes of Parkinson Disease
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03187301
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 59
- Registration Number
- NCT02969629
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Clinique Beau Soleil
- Target Recruit Count
- 45
- Registration Number
- NCT02940912
- Locations
- 🇫🇷
Chu Ponchaillou, Rennes, France
🇫🇷Hôpital CIVIL, Strasbourg, France
🇫🇷Hôpital de HAUTEPIERRE, Strasbourg, France
Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)
- Conditions
- Parkinson's Disease
- Interventions
- Other: Best Medical Treatment
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT02864004
- Locations
- 🇫🇷
Clermont-Ferrand University Hospital, Clermont-Ferrand, France
🇫🇷Lille University Hospital, Lille, France
🇫🇷Amiens University Hospital, Amiens, France
Apomorphine in Parkinson's Disease Patients With Visual Hallucinations
- Conditions
- Parkinson's DiseaseHallucinations, Visual
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 35
- Registration Number
- NCT02702076
- Locations
- 🇳🇱
Department of Neurology, Groningen, Netherlands
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 15
- Registration Number
- NCT02688465
- Locations
- 🇫🇷
Fondation ophtalmique Adolphe de Rothschild, Paris, France
Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
- Conditions
- Parkinson's DiseaseMotor Symptoms
- Interventions
- Behavioral: Physical Therapy
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT02549573
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT02542696
- Locations
- 🇺🇸
Keck Medical Center at USC, Los Angeles, California, United States
🇺🇸Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸UC Irvine Health Gottschalk Medical Plaza, Irvine, California, United States
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT02469090
- Locations
- 🇨🇦
UHN Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸Emory University Department of Neurology, Atlanta, Georgia, United States
🇺🇸The Research Center of Southern California, Oceanside, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.